MTOR and cancer: There are also active clinical trials that include combination treatments for PTEN-inactive cancer types such as (i) the combination of PI3K-Beta inhibitor, AZD8186, and chemotherapeutic drug, docetaxel (NCT03218826), (ii) the combination of receptor tyrosine kinase inhibitor, pazopanib, and mTOR inhibitor, everolimus (NCT01430572), and (iii) the combination of PI3K-Beta inhibitor, GSK2636771, and immunotherapy, pembrolizumab (NCT03131908).